Across TCGA pan-cancer cohorts, GPRIN3 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of GPRIN3’s most consistent transcriptional readouts.
The strongest signal is observed in stomach adenocarcinoma (STAD), where GPRIN3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types GPRIN3 is over-expressed in tumor, although a few such as LUSC and LUAD show the opposite, repressed pattern.
STAD, LUSC, and KICH are the cancer types where GPRIN3 tumor–normal differential expression is most reproducible.
RNA tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GPRIN3 RNA (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.